NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400

Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400

1.1 Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta400

Site by Devopa
© Copyright 2019 NHS. All rights reserved.